Vice-chairman
Olafur Gudmundsson, born in 1969, is currently the Head of Discovery Pharmaceutics and Analytical Sciences at Bristol-Myers Squibb (BMS), a global biopharmaceutical company. For more than two decades, Gudmundsson has held roles of increasing responsibility within research and development, covering multiple therapeutic areas and stages of drug discovery, both for Bristol-Myers Squibb and Genentech. During his tenure at BMS, Gudmundsson has helped bring multiple drug candidates to clinical trials, several of which have become marketed products. In his time within the pharmaceutical industry, Gudmundsson’s responsibilities have included involvement with global portfolio strategy, evaluation of external acquisitions, strategic innovations, and integration of merged companies.
Gudmundsson has participated in governance teams providing input on global portfolio optimization and prioritization, lead process optimization teams and chaired integration teams.
Gudmundsson is also associated with the graduate program of the Pharmaceutical Chemistry department at Purdue University. Currently, Gudmundsson is a Board member of Eyrir Invest and Noruz.
Gudmundsson has no interest links with the Company’s main customers. He is a member of the Board of Directors of Eyrir Invest, Marel’s largest shareholder.
Education
- PhD, Pharmaceutical Chemistry, University of Kansas
- Cand. pharm., Pharmacy, University of Iceland
Board of directors
- Vice-Chairman since 2021
- Board Director since 2014
Sub-committees
- Remuneration Committee
- Nomination Committee
Holdings in Marel
- 1,705,427 shares (as of 30 August 2022)
